EFFICACY AND SAFETY OF REPEATED INTERMITTENT TREATMENT WITH ELTROMBOPAG IN PATIENTS WITH CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
Psaila B. et al, (2008), HAEMATOLOGICA, 93, 120 - 120
EFFICACY AND SAFETY OF REPEATED INTERMITTENT TREATMENT WITH ELTROMBOPAG IN PATIENTS WITH CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
Psaila B. et al, (2008), HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 93, 120 - 120
Regulation of vasculogenesis by platelet-mediated recruitment of bone marrow-derived cells.
Rafii DC. et al, (2008), Arterioscler Thromb Vasc Biol, 28, 217 - 222
Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
Bussel JB. et al, (2007), N Engl J Med, 357, 2237 - 2247
Comparison of platelet function and bleeding in thrombocytopenic patients with immune thrombocytopenic purpura (ITP) and chemotherapy-induced thrombocytopenia (CIT)
Psaila B. et al, (2007), BLOOD, 110, 624A - 624A
In vivo effects of eltrombopag on human platelet function
Psaila B. et al, (2007), BLOOD, 110, 391A - 392A
Immune thrombocytopenic purpura.
Psaila B. and Bussel JB., (2007), Hematol Oncol Clin North Am, 21, 743 - vii
The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP.
Page LK. et al, (2007), Br J Haematol, 138, 245 - 248
Immature platelet fraction: Insight into mechanisms of response to treatment in immune thrombocytopenic purpura
Psaila B. et al, (2007), INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 29, 25 - 25
Eltrombopag, an oral platelet growth factor, for treatment of chronic immune thrombocytopenic purpura (ITP): A randomized, double-blind, placebo-controlled trial
Bussel JB. et al, (2007), Journal of Supportive Oncology, 5, 66 - 67
Hospital staff should use more than one method to detect adverse events and potential adverse events: incident reporting, pharmacist surveillance and local real-time record review may all have a place.
Olsen S. et al, (2007), Qual Saf Health Care, 16, 40 - 44
Niche-to-niche migration of bone-marrow-derived cells.
Kaplan RN. et al, (2007), Trends Mol Med, 13, 72 - 81
Novel thrombopoietic agents.
Andemariam B. et al, (2007), Hematology Am Soc Hematol Educ Program, 106 - 113
Bone marrow cells in the 'pre-metastatic niche': within bone and beyond.
Kaplan RN. et al, (2006), Cancer Metastasis Rev, 25, 521 - 529
Insights into therapeutic mechanisms: Measuring immature platelet fraction (IPF) describes response to treatment in immune thrombocytopenic purpura (ITP).
Psaila B. et al, (2006), BLOOD, 108, 319A - 319A
A case for measuring apoprotein B
Psaila B. and Betteridge DJ., (2006), Case Studies in Lipid Management, 109 - 112
From bone marrow niche to pre-metastatic niche
Kaplan R. et al, (2006), CANCER TREATMENT REVIEWS, 32, S17 - S17
Priming the 'soil' for breast cancer metastasis: the pre-metastatic niche.
Psaila B. et al, (2006), Breast Dis, 26, 65 - 74